• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Adagene Inc.

    1/29/26 4:16:34 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAG alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Adagene Inc.

    (Name of Issuer)


    Ordinary Shares

    (Title of Class of Securities)


    005329107

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    Smith Vincent C
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,301,631.25
    6Shared Voting Power

    3,793,720.00
    7Sole Dispositive Power

    1,301,631.25
    8Shared Dispositive Power

    3,793,720.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,095,351.25
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.7 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  (1) Includes sole voting and dispositive power over 1,301,631.25 Ordinary Shares held directly, and shared voting and dispositive power over (i) 3,608,018.75 Ordinary Shares held by The Vincent C. Smith, Jr. 2025 Annuity Trust and (ii) 185,701.25 Ordinary Shares held by VCS Master Holdings GP. Mr. Smith is a trustee of The Vincent C. Smith, Jr. 2025 Annuity Trust therefore may be deemed to have beneficial ownership of the shares held thereby. Mr. Smith is the grantor of all of the trusts that are partners of VCS Master Holdings GP and disclaims beneficial ownership of the shares held thereby. (2) Represents Ordinary Shares held by the Reporting Person. There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 005329 107 has been assigned to the ADSs of the Issuer, which are quoted on NASDAQ Stock Market under the symbol "ADAG." Each ADS represents one and one quarter Ordinary Share.


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    The Vincent C. Smith, Jr. 2025 Annuity Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,608,018.75
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,608,018.75
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,608,018.75
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) Mr. Smith is a trustee of The Vincent C. Smith, Jr. 2025 Annuity Trust and therefore may be deemed to have beneficial ownership of the shares held thereby. (2) Represents the ordinary shares, par value $0.0001 per share of the Issuer ("Ordinary Shares") held by the Reporting Person. There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 005329 107 has been assigned to the American depositary shares ("ADSs") of the Issuer, which are quoted on NASDAQ Stock Market under the symbol "ADAG." Each ADS represents one and one quarter Ordinary Share.


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    VCS Master Holdings GP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    185,701.25
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    185,701.25
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    185,701.25
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.0 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) Mr. Smith is the grantor of all of the trusts that are partners of VCS Master Holdings GP, and disclaims beneficial ownership of the shares held thereby. (2) Represents Ordinary Shares held by the Reporting Person. There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 005329 107 has been assigned to the ADSs of the Issuer, which are quoted on NASDAQ Stock Market under the symbol "ADAG." Each ADS represents one and one quarter Ordinary Share.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Adagene Inc.
    (b)Address of issuer's principal executive offices:

    4F, BUILDING C14, NO. 218, XINGHU STREET, SUZHOU INDUSTRIAL PARK, JIANGSU, CHINA, 00000.
    Item 2. 
    (a)Name of person filing:

    This Statement is filed on behalf of each of the following: (i) The Vincent C. Smith, Jr. 2025 Annuity Trust (the "2025 Annuity Trust"); (ii) VCS Master Holdings GP, a Delaware General Partnership ("VCS"); and (iii) Vincent C. Smith, an individual ("Mr. Smith", and together with the 2025 Annuity Trust and VCS, the "Reporting Persons"). Mr. Smith is a trustee of the 2025 Annuity Trust therefore may be deemed to have beneficial ownership of the shares held thereby. Mr Smith is the grantor of all the trusts that are the partners of VCS, and disclaims beneficial ownership of the shares held thereby.
    (b)Address or principal business office or, if none, residence:

    The mailing address for each of the Reporting Persons is 17595 Harvard Avenue, Suite C511, Irvine, California 92614.
    (c)Citizenship:

    (i) The Vincent C. Smith, Jr. 2025 Annuity Trust, a trust organized under the laws of the State of California; (ii) VCS is a general partnership organized under the laws of Delaware; and (iii) Mr. Smith is a citizen of the United States of America.
    (d)Title of class of securities:

    Ordinary Shares
    (e)CUSIP No.:

    005329107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    (i) The 2025 Annuity Trust beneficially owns an aggregate of 3,608,019 Ordinary Shares; (ii) VCS beneficially owns an aggregate of 185,701 Ordinary Shares; and (iii) Mr. Smith may be deemed to beneficially own an aggregate of 5,095,351 Ordinary Shares, including 1,301,631 Ordinary Shares held directly, 3,608,019 Ordinary Shares held by the 2025 Annuity Trust and 185,701 Ordinary Shares held by VCS.
    (b)Percent of class:

    The percentage of shares beneficially owned by the Reporting Persons below is based upon 58,914,087 of the Issuer's Ordinary Shares outstanding as of June 30, 2025, as set forth in the Issuer's Registration Statement on Form F-1 filed with the Securities and Exchange Commission on October 31, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Mr. Smith: 1,301,631 2025 Annuity Trust: 0 VCS: 0

     (ii) Shared power to vote or to direct the vote:

    Mr. Smith: 3,793,720 2025 Annuity Trust: 3,608,019 VCS: 185,701

     (iii) Sole power to dispose or to direct the disposition of:

    Mr. Smith: 1,301,631 2025 Annuity Trust: 0 VCS: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Mr. Smith: 3,793,720 2025 Annuity Trust: 3,608,019 VCS: 185,701

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Smith Vincent C
     
    Signature:/s/ Vincent C. Smith
    Name/Title:Individual
    Date:01/29/2026
     
    The Vincent C. Smith, Jr. 2025 Annuity Trust
     
    Signature:/s/ Vincent C. Smith
    Name/Title:Trustee
    Date:01/29/2026
     
    VCS Master Holdings GP
     
    Signature:/s/ Jerry Rickmeyer
    Name/Title:Trustee & Partner
    Date:01/29/2026
    Get the next $ADAG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAG

    DatePrice TargetRatingAnalyst
    11/24/2025$9.00Buy
    Guggenheim
    8/6/2025$7.00Outperform
    Leerink Partners
    1/31/2025Overweight → Equal-Weight
    Morgan Stanley
    2/1/2022$27.00 → $15.00Overweight
    Morgan Stanley
    More analyst ratings

    $ADAG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adagene Provides Business Update and 2026 Objectives

    Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated to provide sufficient runway into late 2027 SAN DIEGO and SUZHOU, China, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced year-end unaudited cash and cash equivalents of $74.5 million and provided a business update. 2025 Key Accomplishments: Phase 1b/2 trial results with muzastotug in MSS CRC at ASCO: Shared updated data from 10 mg/kg and 20 mg/

    1/23/26 8:00:00 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

    Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated muzastotug, in combination with Merck's (known as MSD outside of the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as a Fast Track product for adult patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) without current or active liver metastases. Muzas

    12/16/25 7:00:00 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

    SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG) and Third Arc Bio, Inc. ("Third Arc Bio"), today announced a licensing agreement under which Third Arc Bio will utilize Adagene's SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumor associated antigens. Under the terms of the agreement, Third Arc Bio will receive rights to research, develop and commercialize two candidate molecules worldwide. Adagene will receive an upfront payment of $5 million and is eligible to receive development and commercial-based milestones of up to $840 million (if all milestones and conditions are achieve

    11/13/25 7:00:00 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Adagene Inc.

    SCHEDULE 13G/A - Adagene Inc. (0001818838) (Subject)

    1/29/26 4:16:34 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Adagene Inc.

    6-K - Adagene Inc. (0001818838) (Filer)

    1/23/26 8:00:14 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Adagene Inc.

    EFFECT - Adagene Inc. (0001818838) (Filer)

    1/12/26 12:15:24 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Adagene with a new price target

    Guggenheim initiated coverage of Adagene with a rating of Buy and set a new price target of $9.00

    11/24/25 8:15:55 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Adagene with a new price target

    Leerink Partners initiated coverage of Adagene with a rating of Outperform and set a new price target of $7.00

    8/6/25 7:24:59 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene downgraded by Morgan Stanley

    Morgan Stanley downgraded Adagene from Overweight to Equal-Weight

    1/31/25 8:29:36 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    Leadership Updates

    Live Leadership Updates

    View All

    Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

    SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor. "Adagene is advancing the field of Immuno-Oncology with its pipeline of innovative antibodies centered around CTLA-4, a master-regulator of T-cell responses. This includes ADG116 to differentially engage CTLA-4 for greater T-reg depletion, and ADG126 to mask the CTLA-4 binder (ADG116) until it reaches the tumor microenvironment aiming for an enhanced efficacy and reduced toxicity profile. The design of these antibodies may allow a broad

    9/3/25 9:05:21 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

    - Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. "Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells. Their platform has broad potential for enhanced immunotherapy with effective regulatory T-cell depletion, in conjunction with monoclonal antibodies, bispecifics, T-cell engagers, and antibod

    4/28/25 8:00:00 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

    - Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the "SAB"). Dr. Lenz is the Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC and Co-Director of the Center for Cancer Drug Development a

    3/7/24 4:01:00 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    Financials

    Live finance-specific insights

    View All

    Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

    – Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be presented at SITC 2022 – – Masked, anti-CTLA-4 antibody, ADG126, safely dosed repeatedly up to 20 mg/kg as a single agent with encouraging efficacy signals; results to be presented at ESMO 2022 – – Presentation of combination dosing data with anti-PD-1 therapies in 2022, while dose expansion begins for both ADG116 and ADG126 in targeted tumors – – Submitted regulatory filing for clinical trial of masked, IgG1-based anti-CD137 candidate, ADG206, with greater preclinical potency than the analog of

    8/30/22 5:25:00 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Adagene Inc.

    SC 13G/A - Adagene Inc. (0001818838) (Subject)

    11/7/24 4:32:13 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Adagene Inc. (Amendment)

    SC 13D/A - Adagene Inc. (0001818838) (Subject)

    3/1/24 4:30:20 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Adagene Inc. (Amendment)

    SC 13G/A - Adagene Inc. (0001818838) (Subject)

    2/9/24 8:35:54 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care